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Mechanisms of Quinolone Resistance in Clinical Isolates of Shigella dysenteriae
In gram-negative bacteria, gyrase and topoisomerase IV are
primary and secondary targets, respectively, of the fluoro-
quinolones. In addition to the mutations in the genes encoding
the target enzymes (1, 4), quinolone resistance may also be
associated with increased efflux of the drugs (2, 5). Possible
mechanisms of quinolone resistance were investigated in clin-
ical isolates of Shigella dysenteriae obtained from the Interna-
tional Centre for Diarrhoeal Disease Research, Dhaka, Ban-
gladesh (AK) and the National Institute of Cholera and
Enteric Diseases, Calcutta, India (CI, DS, IPB, and IMC). The
quinolone resistance-determining regions (QRDR) of gyrA
and parC were amplified with the primer pairs 59TACACCG
GTCAACATTGAGG39-59TTAATGATTGCCGCCGTCGG39
and 59GTATGCGATGTCTGAACTGGGCCTG39-59CGAC
AACCGGGATTCGGTG39, respectively. The Ser833Leu
substitution appeared sufficient to confer high-level nalidixic
acid resistance (MIC . 250 mg/ml) as determined by standard
methods (3) (Table 1). Four strains—DS-1, DS-2, CI-1, and
CI-2—for which the norfloxacin MICs were 2 mg/ml and the
ciprofloxacin MICs were between 0.5 and 1 mg/ml harbored the
mutation Asp873Gly in GyrA. None of the isolates examined
had any mutations in the QRDR-encoding part of the parC
gene.
Accumulation of norfloxacin was studied as described by
Ghosh et al. (2) by using carbonyl cyanide m-chlorophenylhy-
drazone (CCCP) (100 mM) as proton motive force (PMF)
uncoupler. The DS, CI, and AK series (with the exception of
AK 19520) showed steady-state levels of norfloxacin accumu-
lation (both before and after addition of CCCP) similar to
those for the susceptible strain AK19520 (Table 1)—evidence
against involvement of a PMF-dependent efflux pump in resis-
tance in these strains. Considering the DS and CI series, the
mutation corresponding to Asp873Gly therefore appeared
sufficient to confer approximately 10-fold resistance to the
fluoroquinolones in comparison with AK19520. On the other
hand, the accumulation of norfloxacin at steady state (before
addition of CCCP) was less in the IPB and IMC series in
comparison with AK19520. Addition of CCCP increased the
level of accumulation in these resistant strains to a level com-
parable to that of AK19520, suggesting a role of a PMF-
dependent efflux pump in the development of resistance. Since
these strains lacked gyrA or parC mutations in the QRDR,
increased efflux pump activity appears likely to be sufficient to
confer 20- to 80-fold resistance to the fluoroquinolones com-
pared to AK19520. We have previously shown, using isogenic
strains (2), that increased efflux of the fluoroquinolones may be
a mechanism of development of fluoroquinolone resistance.
The data obtained in this study with clinical isolates supports
this notion. However, the possible involvement of gyrB or parE
mutations in the decreased susceptibilities of the isolates to
quinolones cannot be excluded.
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TABLE 1. Quinolone susceptibility, alterations in GyrA, and norfloxacin accumulation in clinical isolates of S. dysenteriaea
Strain(s)
MIC (mg/ml) Codon change at position: Accumulation of NFLXb
NAL NFLX OFLX CFLX 83 87 Before additionof CCCP
After addition
of CCCP
AK19520 16 0.25 0.25 0.25 —c — 0.23 6 0.01 0.34 6 0.013
AK21104 .250 2 1 2 Ser (TTG)3Leu (TCG) — 0.22 6 0.005 0.33 6 0.012
AK27228 .250 2 2 2 Ser (TTG)3Leu (TCG) — 0.22 6 0.005 0.33 6 0.011
AK24467 .250 2 1 2 Ser (TTG)3Leu (TCG) — 0.22 6 0.005 0.32 6 0.013
AK21809 .250 2 1 4 Ser (TTG)3Leu (TCG) — 0.23 6 0.010 0.33 6 0.014
IPB32, IPB34,
IMC118, IMC119
32 16 4 4 — — 0.10 6 0.001 0.30 6 0.012
IPB38 16 16 4 4 — — NDd ND
IMC67 16 16 4 4 — — 0.10 6 0.001 0.30 6 0.013
DS-1, DS-2 64 2 2 0.5 — Asp (GAC)3Gly (GGC) 0.25 6 0.010 0.32 6 0.014
CI-1, CI-2 64 2 2 1 — Asp (GAC)3Gly (GGC) 0.23 6 0.010 0.33 6 0.012
a NAL, nalidixic acid; NFLX, norfloxacin; OFLX, ofloxacin; CFLX, ciprofloxacin.
b The data are means of three determinations 6 standard deviations, expressed in micrograms per milligram (dry weight) of cells.
c —, identical to the codon in E. coli.
d ND, not determined.
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